Lyra Therapeutics Inc expected to post a loss of 41 cents a share - Earnings Preview

Lyra Therapeutics

03/03/2023 13:52

* Lyra Therapeutics Inc  LYRA.OQ   LYRA.O  is expected
to show a
fall in quarterly revenue when it reports  results on March 7
(estimated). 
    * The Watertown Massachusetts-based  company is expected to
report
 a 44.0% decrease in revenue to $151.8 thousand from $271
thousand a year ago, according to the mean estimate from 5
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Lyra Therapeutics
Inc is
for a loss of 41 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Lyra
Therapeutics
Inc is $16.5​, above​ its last closing price of $2.33. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.46       -0.44      -0.40     Beat    9.1
 Jun. 30 2022  -0.36       -0.37      -0.43     Missed  -15.4
 Mar. 31 2022  -0.93       -0.91      -0.54     Beat    41​
 Dec. 31 2021  -0.79       -0.79      -1.05     Missed  -32.9
 ​​Sep.        -0.73       -0.73      -0.85     Missed  -15.6
 30 2021                                                
 Jun. 30 2021  -0.59       -0.59      -0.85     Missed  -43.3​
 Mar. 31 2021  -0.48       -0.48      -0.60     Missed  -25
 Dec. 31 2020  -0.59       -0.56      -0.46     Beat    17.9
 This summary was machine generated March 3 at 13:52 GMT.  All
figures in US dollars  unless otherwise stated